share_log

和鉑醫藥-B：截至二零二三年十二月三十一日止年度的年度業績公告

HBM HOLDINGS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 28 07:19
Summary by Moomoo AI
和鉑醫藥控股有限公司（「和鉑醫藥」）公佈截至2023年12月31日止年度的業績。期內，公司收入達89,502千美元，較去年同期增長119.9%，主要得益於分子許可費、研究服務費及技術許可費的增加。研發開支較去年同期下降66.6%至45,081千美元，行政開支亦下降28.6%至19,498千美元。公司年內溢利為22,763千美元，而去年同期為虧損137,268千美元。公司於年內無派發股息。截至2023年12月31日，公司現金及現金等價物為140,324千美元。公司於年內繼續推進多項臨床試驗，包括巴托利單抗、普魯蘇拜單抗等多個產品的研發，並與多家生物技術公司達成合作協議，進一步擴大其研發及商業化網絡。
和鉑醫藥控股有限公司（「和鉑醫藥」）公佈截至2023年12月31日止年度的業績。期內，公司收入達89,502千美元，較去年同期增長119.9%，主要得益於分子許可費、研究服務費及技術許可費的增加。研發開支較去年同期下降66.6%至45,081千美元，行政開支亦下降28.6%至19,498千美元。公司年內溢利為22,763千美元，而去年同期為虧損137,268千美元。公司於年內無派發股息。截至2023年12月31日，公司現金及現金等價物為140,324千美元。公司於年內繼續推進多項臨床試驗，包括巴托利單抗、普魯蘇拜單抗等多個產品的研發，並與多家生物技術公司達成合作協議，進一步擴大其研發及商業化網絡。
Wa Platinum Pharmaceutical Holdings Limited (“Wa Platinum Pharmaceuticals”) announces results for the year ended 31 December 2023. During the period, the Company's revenue reached $89,502 thousand, an increase of 119.9% year-over-year, primarily due to increases in molecular licensing fees, research service fees and technical licensing fees. R&D expenses decreased 66.6% to $45,081 thousand compared to the same period last year, and administrative expenses decreased 28.6% to $19,498 thousand. The company's profit for the year was $22,763 thousand, compared to a loss of $137,268 thousand in the same period last year. The company did not distribute dividends during the year. As of December 31, 2023, the Company's cash and cash equivalents were $140,324 thousand. During the year, the Company continued to advance several clinical trials, including the development of several products such as bartolitone, prosubaitone, and partnered with several biotech companies to further expand its R&D and commercialization network.
Wa Platinum Pharmaceutical Holdings Limited (“Wa Platinum Pharmaceuticals”) announces results for the year ended 31 December 2023. During the period, the Company's revenue reached $89,502 thousand, an increase of 119.9% year-over-year, primarily due to increases in molecular licensing fees, research service fees and technical licensing fees. R&D expenses decreased 66.6% to $45,081 thousand compared to the same period last year, and administrative expenses decreased 28.6% to $19,498 thousand. The company's profit for the year was $22,763 thousand, compared to a loss of $137,268 thousand in the same period last year. The company did not distribute dividends during the year. As of December 31, 2023, the Company's cash and cash equivalents were $140,324 thousand. During the year, the Company continued to advance several clinical trials, including the development of several products such as bartolitone, prosubaitone, and partnered with several biotech companies to further expand its R&D and commercialization network.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more